Skip to Main Content

Advertisement

Skip Nav Destination

Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma

Blood Adv (2022) 6 (11): 3268–3279.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement